Yingqin Wang1, Yaxing Shen2, Xia Sun3,4, Tinah L Hong5, Long Shuang Huang6, Ming Zhong1. 1. Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. 2. Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. 3. Department of Nephrology, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou 221000, China. 4. Cancer Institute, Xuzhou Medical University, Xuzhou 221002, China. 5. New Trier High School, Winnetka, IL, USA. 6. Department of Pharmacology, Shanghai Hospital of Traditional Chinese Medicine, Shanghai 200032, China.
Abstract
BACKGROUND: Sphingosine-1-phosphate (S1P), a bioactive lipid, is generally increased in human non-small cell lung cancer (NSCLC). Evidence has shown that the levels of enzymes in S1P metabolism were associated with clinical outcomes in patients with NSCLC. Nevertheless, the roles of mRNA expression of major enzymes (SPHK1, SPHK2 and SGPL1) in S1P metabolism for predicting outcomes in NSCLC patients have not been determined. METHODS: "The Kaplan-Meier plotter" (the KM plotter) is an online database which contains gene expression and clinical data of 1,928 NSCLC patients. In this study, we analyzed the relationship between mRNA expression of major enzymes in S1P metabolism and overall survival (OS) in 1,926 NSCLC patients with the KM plotter. Further analyses stratified by smoking history, non-metastasis patents, clinical stages, negative surgical margin, chemotherapy and radiotherapy were also performed. RESULTS: High SPHK1 mRNA expression [hazard ratio (HR) 1.47, 95% confident interval (CI): 1.28-1.68, P=2.6e-08] was significantly correlated to worse OS, but high SPHK2 (0.66, 95% CI: 0.59-0.75, P=1.9e-10) or SGPL1 (HR 0.64, 95% CI: 0.55-0.75, P=8.7e-09) mRNA expression was in favor of better OS in NSCLC patients. CONCLUSIONS: The mRNA expression of SPHK1, SPHK2, and SGPL1 is potential predictor of outcomes in NSCLC patients. 2019 Translational Lung Cancer Research. All rights reserved.
BACKGROUND: Sphingosine-1-phosphate (S1P), a bioactive lipid, is generally increased in human non-small cell lung cancer (NSCLC). Evidence has shown that the levels of enzymes in S1P metabolism were associated with clinical outcomes in patients with NSCLC. Nevertheless, the roles of mRNA expression of major enzymes (SPHK1, SPHK2 and SGPL1) in S1P metabolism for predicting outcomes in NSCLC patients have not been determined. METHODS: "The Kaplan-Meier plotter" (the KM plotter) is an online database which contains gene expression and clinical data of 1,928 NSCLC patients. In this study, we analyzed the relationship between mRNA expression of major enzymes in S1P metabolism and overall survival (OS) in 1,926 NSCLC patients with the KM plotter. Further analyses stratified by smoking history, non-metastasis patents, clinical stages, negative surgical margin, chemotherapy and radiotherapy were also performed. RESULTS: High SPHK1 mRNA expression [hazard ratio (HR) 1.47, 95% confident interval (CI): 1.28-1.68, P=2.6e-08] was significantly correlated to worse OS, but high SPHK2 (0.66, 95% CI: 0.59-0.75, P=1.9e-10) or SGPL1 (HR 0.64, 95% CI: 0.55-0.75, P=8.7e-09) mRNA expression was in favor of better OS in NSCLC patients. CONCLUSIONS: The mRNA expression of SPHK1, SPHK2, and SGPL1 is potential predictor of outcomes in NSCLC patients. 2019 Translational Lung Cancer Research. All rights reserved.
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Sathya Narayanan Patmanathan; Steven P Johnson; Sook Ling Lai; Suthashini Panja Bernam; Victor Lopes; Wenbin Wei; Maha Hafez Ibrahim; Federico Torta; Pradeep Narayanaswamy; Markus R Wenk; Deron R Herr; Paul G Murray; Lee Fah Yap; Ian C Paterson Journal: Sci Rep Date: 2016-05-10 Impact factor: 4.379